John R. Lowe

Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo

John R. Lowe, James Araujo, Jihong Yang et al. · Experimental Eye Research · 2007 · 166 citations

Inflammation, Angiogenesis, Medicine +9

Sequence and analysis of the DNA encoding protective antigen of Bacillus anthracis

Susan L. Welkos, John R. Lowe, F Eden-McCutchan et al. · Gene · 1988 · 161 citations

Protective Antigen, Natural Sciences, Pathogenesis +10

Characterization of lethal factor binding and cell receptor binding domains of protective antigen of Bacillus anthracis using monoclonal anti bodies

Stephen F. Little, Jeanne M. Novak, John R. Lowe et al. · Microbiology · 1996 · 127 citations

Specific Immune Response to Phospholipase B-Like 2 Protein, a Host Cell Impurity in Lebrikizumab Clinical Material

Saloumeh K Fischer, Melissa Cheu, Kun Peng et al. · The AAPS Journal · 2016 · 112 citations

Inflammation, Host Response, Autoimmune Disease +13

Enhanced tumor killing by Apo2L/TRAIL and CPT-11 co-treatment is associated with p21 cleavage and differential regulation of Apo2L/TRAIL ligand and its receptors

Hong Xiang, Judith A. Fox, Klára Tótpál et al. · Oncogene · 2002 · 50 citations

Apo2l/trail Ligand, Enhanced Tumor, P21 Cleavage +10